Burn injuries are notoriously difficult to treat due to the complex and multifactorial nature of skin damage and repair. The prevailing treatment, autologous skin grafting, while effective, is limited by significant drawbacks including donor site morbidity, limited availability of healthy skin, and prolonged healing times. These limitations often exacerbate patient discomfort and elevate healthcare burdens. The innovative 4-AP hydrogel represents a paradigm shift, leveraging localized drug delivery to stimulate intrinsic regenerative pathways while circumventing systemic side effects.

The active ingredient, 4-aminopyridine, is widely known for its utility in managing multiple sclerosis under the trade name Ampyra. Its mechanism of action enhances neural conduction by blocking potassium channels, but intriguingly, previous studies revealed its influence on keratinocytes and fibroblasts—cell populations essential to wound healing and tissue remodeling. However, systemic administration posed severe risks including seizures. The current gel formulation overcomes these challenges by embedding 4-AP within a biocompatible laponite-gelatin matrix, enabling controlled and localized release directly at the wound site.

This delivery system capitalizes on the unique physicochemical properties of laponite nanosilicates combined with gelatin, providing both structural stability and biocompatibility. The hydrogel matrix ensures a sustained release of 4-AP, maintaining therapeutic concentrations within the wound microenvironment without spillover into systemic circulation. Compatibility assays confirmed that the gel supports cell viability and proliferation, fostering an environment conducive to tissue regeneration while minimizing inflammation.

Quantitative evaluation of wound healing demonstrated impressive efficacy. In vitro models exhibited over 90% wound closure within 48 hours, underscoring rapid epithelial migration and cell proliferation. In vivo animal studies revealed a significant reduction in wound size beginning from day six post-application, culminating in near-total closure by day 21. In stark contrast, untreated control wounds remained partially open throughout the observation period, highlighting the potent regenerative effect attributed to the 4-AP gel.

Histological and molecular analyses provided further insights into the gel’s mechanism of action. The treatment modulated the inflammatory response, effectively reducing pro-inflammatory markers which often impair wound closure. It enhanced re-epithelialization by accelerating keratinocyte mobilization and proliferation. Additionally, angiogenesis—the formation of new blood vessels critical for delivering oxygen and nutrients—was markedly increased, facilitating robust tissue repair.

A hallmark of high-quality wound healing is the restoration of the extracellular matrix, primarily through the deposition of collagen types I and III. The 4-AP gel significantly amplified collagen synthesis, with type I collagen levels rising by 438% and type III by 288% compared with controls. Furthermore, the collagen I/III ratio indicated enhanced maturation and remodeling of wound tissue, a factor closely associated with functional recovery and reduced scarring. Importantly, the gel also promoted the transformation of fibroblasts into myofibroblasts, specialized cells that contribute to wound contraction and matrix remodeling.

The strategic repurposing of 4-AP leverages its well-established safety profile, thereby streamlining the regulatory pathway toward clinical application. Unlike novel drug entities, this approach benefits from extensive prior pharmacokinetic and toxicity data, potentially accelerating the translational process. The integration of material science with pharmacology exemplifies a cutting-edge approach to therapeutic innovation—melding existing drugs with advanced biomaterials to address unmet clinical needs.

Looking ahead, the research team envisions progressing the 4-AP topical gel through rigorous clinical trials to validate safety and efficacy in human patients. The potential to minimize invasive procedures, reduce healing times, and improve patient outcomes could substantially alter burn wound management paradigms worldwide. Additionally, this technology may pave the way for developing similar localized delivery systems for other drugs traditionally limited by systemic toxicity.

This discovery aligns with the broader mission of the Terasaki Institute for Biomedical Innovation to harness translational research in developing practical biomedical technologies. Through interdisciplinary collaboration, combining expertise in biomaterials, cellular engineering, and clinical sciences, the institute continues to pioneer therapies that enhance quality of life and reshape healthcare.

The significance of this study extends beyond burn care alone; it opens new avenues for regenerative medicine and tissue engineering. By demonstrating controlled, localized drug delivery’s effectiveness in a challenging wound model, the research provides a template for tackling various traumatic injuries and chronic wounds. The synergy between pharmacology and biomaterials ushered in by this work signals a promising future for personalized, targeted therapeutics.

In summary, the development of a 4-aminopyridine-loaded laponite-gelatin gel marks a remarkable step forward in non-invasive burn wound therapy. Its ability to accelerate wound closure, modulate inflammatory responses, enhance angiogenesis, and optimize collagen deposition offers a multifaceted approach to skin regeneration. This innovative treatment harbors the potential to transform clinical practice, reduce patient suffering, and alleviate healthcare costs associated with burn injuries.

For further inquiries, Dr. Johnson V. John, Assistant Professor at the Terasaki Institute for Biomedical Innovation, stands as the principal contact for this pioneering work. His commitment to advancing regenerative technologies underscores the potent promise of this topical gel therapy in reshaping wound care landscapes globally.

Subject of Research: Not applicable
Article Title: 4-aminopyridine-loaded topical gel for promoting skin regeneration in burn injuries
News Publication Date: June 4, 2026
Web References: DOI: 10.1016/j.biomaterials.2026.124293
References: Research published in Biomaterials journal
Image Credits: Terasaki Institute for Biomedical Innovation

Keywords

Health and medicine, Regenerative medicine, Wound healing, Tissue engineering, Biomaterials, Translational medicine, Burn wounds

The newly formulated hydrogel, composed of hyaluronic acid modified with glycidyl methacrylate (HA-GMA), exhibits a highly porous, water-rich network that rapidly absorbs and releases its viral cargo predominantly through diffusion mechanisms. This material architecture fosters a controlled release profile, enabling the encapsulated recombinant adeno-associated virus serotype 8 (AAV8) vector encoding a soluble TGF-β receptor II (sTβRII) to be locally enriched during critical phases of healing but without lingering excessively beyond three days. The temporary nature of the hydrogel’s presence is key, preventing unwanted chronic exposure while ensuring maximal gene transfer during the wound’s escalation phase of fibrosis.

In vivo experiments utilizing a mouse full-thickness skin wound model demonstrated the delivery system’s precision. Upon application, the poly-(HA-GMA) hydrogel loaded with AAV8-sTβRII efficiently transduced both the cutaneous and fascial layers surrounding the wound. The hydrogel-dependent delivery method markedly restricted viral vector dissemination to systemic organs such as the liver, a well-known off-target site associated with safety concerns in gene therapy. This localized transduction contrasted sharply with more conventional direct intradermal injection, which showed limited tissue selectivity and higher liver exposure.

The therapeutic impact manifested strikingly from postoperative day six onward. Mice treated with the hydrogel harboring the gene therapy exhibited accelerated wound closure compared to controls. Histological analyses revealed a significantly thinner dermis and a more organized collagen fiber arrangement, hallmarks of improved tissue remodeling that reduce the propensity for hypertrophic scarring. Quantitative evaluation noted a diminished collagen area fraction, indicating suppressed excessive extracellular matrix deposition, which is the pathological substrate of fibrosis.

At the molecular and cellular level, immunohistochemical staining confirmed the presence of Flag-tagged sTβRII protein within the scar tissue, verifying successful local expression of the therapeutic receptor. Mechanistic insights became evident by monitoring the canonical TGF-β/Smad signaling pathway—a principal driver of fibroblast activation and collagen production during fibrosis. The treated wounds showed a marked reduction in phosphorylated Smad2/3, the activated forms that propagate fibrogenic signaling, as well as decreased alpha-smooth muscle actin (α-SMA), a marker of myofibroblast differentiation. However, total Smad2/3 protein levels remained largely unaltered, confirming that the therapeutic effect arises from blockade of pathway activation rather than protein downregulation.

Critically, the specificity of the sTβRII’s inhibitory action on TGF-β signaling was rigorously tested. Administration of exogenous TGF-β1 protein reversed the benefits conferred by the AAV8-sTβRII hydrogel treatment, reinstating the fibrotic phenotype both macroscopically and histologically. This rescue experiment underscores the targeted antagonism of TGF-β by the soluble receptor and dispels concerns about off-target effects or nonspecific immune modulation. Such precise molecular targeting is a rare and valuable feature in anti-fibrotic therapies, historically plagued by broad immunosuppression or toxicity.

The choice of AAV8 as the viral capsid serotype provided a particularly advantageous biodistribution profile. Known for efficient transduction in skin tissue and relatively low tropism for the liver, AAV8 ensured high localized expression of sTβRII while minimizing systemic spillover and potential hepatotoxicity. Safety metrics, including stable body weights, serum transaminase levels within normal ranges, and unremarkable histology in principal organs, supported the biocompatibility and clinical translational potential of this combined hydrogel-virus platform.

This innovation epitomizes a materials-biology integrated strategy, precisely aligning the temporal biology of wound healing with molecular intervention at the fibrosis escalation phase. By physically localizing gene delivery and finely controlling the release kinetics through the degradable HA-GMA hydrogel, researchers have circumvented key challenges that have stymied past anti-fibrotic interventions. The end result is a therapeutic modality that improves outcomes from molecular markers and cellular phenotypes all the way to tissue morphology and functional healing.

Beyond the immediate implications for cutaneous wound healing and scar minimization, this platform may herald a broader paradigm shift in localized gene therapy. The modular design allows substitution of different gene cargos and delivery schedules, enabling customization for diverse fibrotic diseases or regenerative medicine applications. As fibrosis underlies a range of chronic conditions—from organ fibrosis to pathological scarring—this demonstration in skin represents a promising proof of concept for wider therapeutic deployment.

Moreover, the study represents a milestone in integrating polymer science, vectorology, and wound biology, showcasing how interdisciplinary approaches can surmount longstanding barriers in regenerative medicine. The rapid hydrogel degradation matched to the early wound healing timeline, combined with AAV capsid serotype engineering, provides a versatile “on-demand” gene therapy strategy, mitigating systemic risks commonly associated with viral vectors.

Collectively, these findings elucidate a powerful anti-fibrotic approach embodied in the “HA-GMA × AAV8-sTβRII” system that taps into endogenous biological rhythms and feedback loops. By selectively blocking profibrotic signaling only after the wound has sufficiently closed, this therapy preserves necessary inflammation and repair processes while halting pathological scar formation. This sophisticated balancing act—guided by robust materials science and viral vector design—could dramatically improve clinical outcomes for countless patients suffering from disfiguring scars or debilitating fibrosis.

The future prospects of this technology are vast. Scaling this platform for large animal models and human clinical trials could unlock transformative therapies for burns, surgical wounds, and chronic ulcers, reducing morbidity and improving quality of life. Additionally, the adaptable hydrogel matrix could be engineered for triggered or prolonged release, further refining temporal control over therapeutic gene expression.

In summary, the study offers a visionary blueprint for harnessing biomaterials and genetic tools in concert to orchestrate healing at the wound edge with unprecedented specificity. Through elegant control of spatial delivery and pathway timing, this approach achieves the coveted goal of attenuating fibrosis without compromising regeneration—an advancement poised to revolutionize scar management and fibrosis treatment on a global scale.

Subject of Research:
Localized gene therapy for scar reduction through targeted inhibition of TGF-β signaling during wound healing using a hydrogel-based delivery system.

Article Title:
The poly-(HA-GMA) hydrogel carrying AAV8-sTβRII alleviates scar formation in mice skin wound healing by inhibiting fibrosis.

Article References:
Chen, J., Zhan, L., Duan, J. et al. The poly-(HA-GMA) hydrogel carrying AAV8-sTβRII alleviates scar formation in mice skin wound healing by inhibiting fibrosis. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00608-2

Image Credits: AI Generated

DOI: 01 April 2026